Bio-Rad Laboratories, Inc. (BIO) EV/EBIT Ratio: 36.51x
Is Bio-Rad Laboratories, Inc.’s EV/EBIT ratio high or low?
Bio-Rad Laboratories, Inc.'s EV/EBIT ratio of 36.51x is in line with its 5-year average of 33.28x, around the middle of its 5-year range (22.61x–47.78x).
The EV/EBIT ratio for Bio-Rad Laboratories, Inc. (BIO) is 36.51x as of Wednesday, June 10, 2026. It is below its 12-month average by 3.99% (38.03x).
BIO EV/EBIT Ratio Chart
BIO Average EV/EBIT Ratio Chart
BIO Current vs Average EV/EBIT Ratio Chart
BIO EV/EBIT Ratio Metrics
EV/EBIT RATIO
36.51x
EV/EBIT RATIO AVG TTM
38.03x
EV/EBIT RATIO AVG 3Y
32.82x
EV/EBIT RATIO AVG 5Y
33.28x
EV/EBIT RATIO AVG 10Y
55.29x
EV/EBIT RATIO AVG 15Y
42.14x
EV/EBIT RATIO AVG 20Y
34.96x
CURRENT VS TTM AVG
-3.99%
CURRENT VS 3Y AVG
+11.23%
CURRENT VS 5Y AVG
+9.69%
CURRENT VS 10Y AVG
-33.97%
CURRENT VS 15Y AVG
-13.36%
CURRENT VS 20Y AVG
+4.42%
BIO Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 36.51x | 38.03x | 32.82x | 33.28x |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 25.46x | 62.90x | 38.55x | 35.16x |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | 239.52x | 98.85x | 147.38x | 147.38x |
| Baxter International Inc. (BAX) | $10.49B | N/A | 442.63x | 243.35x | 134.31x |
| Align Technology, Inc. (ALGN) | $12.56B | 19.62x | 19.31x | 26.46x | 31.52x |
| Hologic, Inc. (HOLX) | $16.97B | 24.28x | 22.66x | 24.05x | 18.32x |
| Moderna, Inc. (MRNA) | $18.40B | N/A | 23.08x | 30.94x | 30.94x |
| BioNTech SE (BNTX) | $21.81B | N/A | 4.91x | 5.85x | 5.85x |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 21.94x | 26.09x | 26.29x | 29.26x |
| Waters Corporation (WAT) | $23.83B | 54.60x | 27.55x | 26.51x | 26.24x |
Bio-Rad Laboratories, Inc. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Bio-Rad Laboratories, Inc. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The EV/EBIT ratio for BIO stock is 36.51x.
- Is Bio-Rad Laboratories, Inc.'s EV/EBIT ratio high or low?
- Bio-Rad Laboratories, Inc.'s EV/EBIT ratio of 36.51x is in line with its 5-year average of 33.28x, around the middle of its 5-year range (22.61x–47.78x).
- What is the TTM average EV/EBIT ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The TTM average EV/EBIT ratio for BIO stock is 38.03x.
- What is the 3Y average EV/EBIT ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 3Y average EV/EBIT ratio for BIO stock is 32.82x.
- What is the 5Y average EV/EBIT ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 5Y average EV/EBIT ratio for BIO stock is 33.28x.
- What is the 10Y average EV/EBIT ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 10Y average EV/EBIT ratio for BIO stock is 55.29x.
- What is the 15Y average EV/EBIT ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 15Y average EV/EBIT ratio for BIO stock is 42.14x.
- What is the 20Y average EV/EBIT ratio for Bio-Rad Laboratories, Inc. (BIO)?
- The 20Y average EV/EBIT ratio for BIO stock is 34.96x.
Bio-Rad Laboratories, Inc. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-10 | 36.51x |
| 2026-06-09 | 37.09x |
| 2026-06-08 | 36.43x |
| 2026-06-05 | 36.77x |
| 2026-06-04 | 38.25x |
| 2026-06-03 | 37.95x |
| 2026-06-02 | 38.09x |
| 2026-06-01 | 38.02x |
| 2026-05-29 | 38.81x |
| 2026-05-28 | 39.46x |
| 2026-05-27 | 38.00x |
| 2026-05-26 | 37.06x |
| 2026-05-22 | 36.02x |
| 2026-05-21 | 35.91x |
| 2026-05-20 | 36.04x |
| 2026-05-19 | 35.27x |
| 2026-05-18 | 35.36x |
| 2026-05-15 | 31.50x |
| 2026-05-14 | 31.36x |
| 2026-05-13 | 31.05x |
| 2026-05-12 | 30.84x |
| 2026-05-11 | 31.08x |
| 2026-05-08 | 32.26x |
| 2026-05-07 | 32.60x |
| 2026-05-06 | 32.79x |
| 2026-05-05 | 32.58x |
| 2026-05-04 | 32.66x |
| 2026-05-01 | 32.51x |
| 2026-04-30 | 35.17x |
| 2026-04-29 | 36.80x |
| 2026-04-28 | 37.30x |
| 2026-04-27 | 38.23x |
| 2026-04-24 | 38.30x |
| 2026-04-23 | 37.54x |
| 2026-04-22 | 39.82x |
| 2026-04-21 | 40.40x |
| 2026-04-20 | 40.13x |
| 2026-04-17 | 39.62x |
| 2026-04-16 | 38.68x |
| 2026-04-15 | 39.26x |
| 2026-04-14 | 38.82x |
| 2026-04-13 | 38.34x |
| 2026-04-10 | 37.29x |
| 2026-04-09 | 37.08x |
| 2026-04-08 | 37.51x |
| 2026-04-07 | 37.14x |
| 2026-04-06 | 37.24x |
| 2026-04-02 | 37.37x |
| 2026-04-01 | 37.18x |
| 2026-03-31 | 37.23x |
| 2026-03-30 | 36.24x |
| 2026-03-27 | 35.65x |
| 2026-03-26 | 36.97x |
| 2026-03-25 | 36.62x |
| 2026-03-24 | 36.45x |
| 2026-03-23 | 35.61x |
| 2026-03-20 | 35.55x |
| 2026-03-19 | 35.61x |
| 2026-03-18 | 35.96x |
| 2026-03-17 | 36.13x |
| 2026-03-16 | 35.16x |
| 2026-03-13 | 35.35x |
| 2026-03-12 | 35.23x |
| 2026-03-11 | 36.18x |
| 2026-03-10 | 35.94x |
| 2026-03-09 | 36.37x |
| 2026-03-06 | 36.18x |
| 2026-03-05 | 37.26x |
| 2026-03-04 | 37.93x |
| 2026-03-03 | 37.40x |
| 2026-03-02 | 37.33x |
| 2026-02-27 | 37.19x |
| 2026-02-26 | 36.81x |
| 2026-02-25 | 36.15x |
| 2026-02-24 | 36.04x |
| 2026-02-23 | 35.99x |
| 2026-02-20 | 36.35x |
| 2026-02-19 | 36.42x |
| 2026-02-18 | 36.27x |
| 2026-02-17 | 35.60x |
| 2026-02-13 | 34.61x |
| 2026-02-12 | 38.84x |
| 2026-02-11 | 39.48x |
| 2026-02-10 | 40.23x |
| 2026-02-09 | 39.63x |
| 2026-02-06 | 40.41x |
| 2026-02-05 | 40.18x |
| 2026-02-04 | 40.94x |
| 2026-02-03 | 40.11x |
| 2026-02-02 | 39.93x |
| 2026-01-30 | 39.48x |
| 2026-01-29 | 39.63x |
| 2026-01-28 | 40.21x |
| 2026-01-27 | 39.96x |
| 2026-01-26 | 40.15x |
| 2026-01-23 | 39.83x |
| 2026-01-22 | 40.86x |
| 2026-01-21 | 41.61x |
| 2026-01-20 | 41.76x |
| 2026-01-16 | 41.85x |
| 2026-01-15 | 42.87x |
| 2026-01-14 | 42.41x |
| 2026-01-13 | 42.88x |
| 2026-01-12 | 42.98x |
| 2026-01-09 | 43.08x |
| 2026-01-08 | 42.51x |
| 2026-01-07 | 43.11x |
| 2026-01-06 | 43.28x |
| 2026-01-05 | 42.90x |
| 2026-01-02 | 40.87x |
| 2025-12-31 | 40.59x |
| 2025-12-30 | 40.77x |
| 2025-12-29 | 40.68x |
| 2025-12-26 | 40.70x |
| 2025-12-24 | 40.44x |
| 2025-12-23 | 40.36x |
| 2025-12-22 | 40.81x |
| 2025-12-19 | 40.42x |
| 2025-12-18 | 40.22x |
| 2025-12-17 | 40.39x |
| 2025-12-16 | 40.48x |
| 2025-12-15 | 41.18x |
| 2025-12-12 | 41.21x |
| 2025-12-11 | 41.90x |
| 2025-12-10 | 42.03x |
| 2025-12-09 | 41.20x |
| 2025-12-08 | 41.25x |
| 2025-12-05 | 42.35x |
| 2025-12-04 | 42.63x |
| 2025-12-03 | 42.66x |
| 2025-12-02 | 42.45x |
| 2025-12-01 | 42.80x |
| 2025-11-28 | 43.20x |
| 2025-11-26 | 43.46x |
| 2025-11-25 | 44.08x |
| 2025-11-24 | 42.92x |
| 2025-11-21 | 42.23x |
| 2025-11-20 | 40.67x |
| 2025-11-19 | 40.81x |
| 2025-11-18 | 41.16x |
| 2025-11-17 | 40.72x |
| 2025-11-14 | 41.81x |
| 2025-11-13 | 42.25x |
| 2025-11-12 | 43.49x |
| 2025-11-11 | 41.83x |
| 2025-11-10 | 41.12x |
| 2025-11-07 | 40.90x |
| 2025-11-06 | 41.02x |
| 2025-11-05 | 41.43x |
| 2025-11-04 | 41.54x |
| 2025-11-03 | 41.60x |
| 2025-10-31 | 42.57x |
| 2025-10-30 | 40.79x |
| 2025-10-29 | 42.56x |
| 2025-10-28 | 44.88x |
| 2025-10-27 | 45.57x |
| 2025-10-24 | 46.01x |
| 2025-10-23 | 45.88x |
| 2025-10-22 | 45.31x |
| 2025-10-21 | 44.98x |
| 2025-10-20 | 43.84x |
| 2025-10-17 | 42.39x |
| 2025-10-16 | 42.68x |
| 2025-10-15 | 41.88x |
| 2025-10-14 | 41.79x |
| 2025-10-13 | 41.62x |
| 2025-10-10 | 40.89x |
| 2025-10-09 | 41.25x |
| 2025-10-08 | 41.52x |
| 2025-10-07 | 40.75x |
| 2025-10-06 | 42.29x |
| 2025-10-03 | 41.84x |
| 2025-10-02 | 40.47x |
| 2025-10-01 | 40.92x |
| 2025-09-30 | 38.78x |
| 2025-09-29 | 37.53x |
| 2025-09-26 | 37.68x |
| 2025-09-25 | 37.57x |
| 2025-09-24 | 38.32x |
| 2025-09-23 | 38.99x |
| 2025-09-22 | 39.14x |
| 2025-09-19 | 39.23x |
| 2025-09-18 | 39.53x |
| 2025-09-17 | 38.77x |
| 2025-09-16 | 39.01x |
| 2025-09-15 | 38.76x |
| 2025-09-12 | 38.78x |
| 2025-09-11 | 39.45x |
| 2025-09-10 | 38.36x |
| 2025-09-09 | 39.46x |
| 2025-09-08 | 40.00x |
| 2025-09-05 | 40.61x |
| 2025-09-04 | 39.88x |
| 2025-09-03 | 39.72x |
| 2025-09-02 | 40.04x |
| 2025-08-29 | 40.91x |
| 2025-08-28 | 40.40x |
| 2025-08-27 | 40.30x |
| 2025-08-26 | 40.76x |
| 2025-08-25 | 40.85x |
| 2025-08-22 | 41.64x |
| 2025-08-21 | 39.35x |
| 2025-08-20 | 39.73x |
| 2025-08-19 | 39.75x |
| 2025-08-18 | 39.30x |
| 2025-08-15 | 39.42x |
| 2025-08-14 | 39.61x |
| 2025-08-13 | 39.61x |
| 2025-08-12 | 38.10x |
| 2025-08-11 | 36.85x |
| 2025-08-08 | 36.81x |
| 2025-08-07 | 36.94x |
| 2025-08-06 | 36.83x |
| 2025-08-05 | 37.78x |
| 2025-08-04 | 38.35x |
| 2025-08-01 | 39.30x |
| 2025-07-31 | 34.10x |
| 2025-07-30 | 31.61x |
| 2025-07-29 | 31.89x |
| 2025-07-28 | 31.97x |
| 2025-07-25 | 33.20x |
| 2025-07-24 | 32.96x |
| 2025-07-23 | 32.40x |
| 2025-07-22 | 31.09x |
| 2025-07-21 | 30.95x |
| 2025-07-18 | 31.20x |
| 2025-07-17 | 31.56x |
| 2025-07-16 | 31.29x |
| 2025-07-15 | 31.30x |
| 2025-07-14 | 31.69x |
| 2025-07-11 | 32.39x |
| 2025-07-10 | 32.71x |
| 2025-07-09 | 31.95x |
| 2025-07-08 | 31.68x |
| 2025-07-07 | 31.27x |
| 2025-07-03 | 31.78x |
| 2025-07-02 | 31.67x |
| 2025-07-01 | 31.37x |
| 2025-06-30 | 30.62x |
| 2025-06-27 | 30.92x |
| 2025-06-26 | 30.87x |
| 2025-06-25 | 30.58x |
| 2025-06-24 | 30.24x |
| 2025-06-23 | 29.97x |
| 2025-06-20 | 30.11x |
| 2025-06-18 | 29.57x |
| 2025-06-17 | 29.40x |
| 2025-06-16 | 29.54x |
| 2025-06-13 | 29.00x |
| 2025-06-12 | 29.62x |
| 2025-06-11 | 29.37x |
| 2025-06-10 | 29.41x |
| 2025-06-09 | 28.85x |
| 2025-06-06 | 28.15x |
| 2025-06-05 | 28.14x |
| 2025-06-04 | 28.45x |
| 2025-06-03 | 28.28x |
| 2025-06-02 | 27.83x |
| 2025-05-30 | 29.00x |
| 2025-05-29 | 29.08x |
Showing the most recent 260 of 4,799 data points. The chart above shows the full history.
Related Metrics
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Norman D. Schwartz